相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Carotid Plaque Inflammation Imaged by PET and Prediction of Recurrent Stroke at 5 Years
John Joseph McCabe et al.
NEUROLOGY (2021)
Monocyte-Chemoattractant Protein-1 Levels in Human Atherosclerotic Lesions Associate With Plaque Vulnerability
Marios K. Georgakis et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2021)
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Matthew J. Page et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
Association of Circulating Monocyte Chemoattractant Protein-1 Levels With Cardiovascular Mortality A Meta-analysis of Population-Based Studies
Marios K. Georgakis et al.
JAMA CARDIOLOGY (2021)
Why Most Acute Stroke Studies Are Positive in Animals but Not in Patients: A Systematic Comparison of Preclinical, Early Phase, and Phase 3 Clinical Trials of Neuroprotective Agents
Antje Schmidt-Pogoda et al.
ANNALS OF NEUROLOGY (2020)
Colchicine in Patients with Chronic Coronary Disease
Stefan M. Nidorf et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Chemokines as Therapeutic Targets in Cardiovascular Disease The Road Behind, The Road Ahead
Heidi Noels et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2019)
Nuclear Focal Adhesion Kinase Controls Vascular Smooth Muscle Cell Proliferation and Neointimal Hyperplasia Through GATA4-Mediated Cyclin D1 Transcription
Kyuho Jeong et al.
CIRCULATION RESEARCH (2019)
Tobacco smoking and risk of 36 cardiovascular disease subtypes: fatal and non-fatal outcomes in a large prospective Australian study
Emily Banks et al.
BMC MEDICINE (2019)
Circulating Monocyte Chemoattractant Protein-1 and Risk of Stroke Meta-Analysis of Population-Based Studies Involving 17 180 Individuals
Marios K. Georgakis et al.
CIRCULATION RESEARCH (2019)
Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction
Jean-Claude Tardif et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
FURIN Inhibition Reduces Vascular Remodeling and Atherosclerotic Lesion Progression in Mice
Gopala K. Yakala et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2019)
Genetically Determined Levels of Circulating Cytokines and Risk of Stroke: Role of Monocyte Chemoattractant Protein-1
Marios K. Georgakis et al.
CIRCULATION (2019)
Low-Dose Methotrexate for the Prevention of Atherosclerotic Events
Paul M. Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Targeting Residual Inflammatory Risk: A Shifting Paradigm for Atherosclerotic Disease
Aaron W. Aday et al.
FRONTIERS IN CARDIOVASCULAR MEDICINE (2019)
Chrono-pharmacological Targeting of the CCL2-CCR2 Axis Ameliorates Atherosclerosis
Carla Winter et al.
CELL METABOLISM (2018)
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
P. M. Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
A novel CCR2 antagonist inhibits atherogenesis in apoE deficient mice by achieving high receptor occupancy
Ilze Bot et al.
SCIENTIFIC REPORTS (2017)
Environmental risk factors and multiple sclerosis: an umbrella review of systematic reviews and meta-analyses
Lazaros Belbasis et al.
LANCET NEUROLOGY (2015)
SYRCLE's risk of bias tool for animal studies
Carlijn R. Hooijmans et al.
BMC MEDICAL RESEARCH METHODOLOGY (2014)
A Novel C-C Chemokine Receptor 2 Antagonist Prevents Progression of Albuminuria and Atherosclerosis in Mouse Models
Masayuki Okamoto et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2012)
Effect of CC Chemokine Receptor 2 CCR2 Blockade on Serum C-Reactive Protein in Individuals at Atherosclerotic Risk and With a Single Nucleotide Polymorphism of the Monocyte Chemoattractant Protein-1 Promoter Region
Jim Gilbert et al.
AMERICAN JOURNAL OF CARDIOLOGY (2011)
The isoenzyme of glutaminyl cyclase is an important regulator of monocyte infiltration under inflammatory conditions
Holger Cynis et al.
EMBO MOLECULAR MEDICINE (2011)
Atherosclerosis: current pathogenesis and therapeutic options
Christian Weber et al.
NATURE MEDICINE (2011)
CCR2 receptor blockade alters blood monocyte subpopulations but does not affect atherosclerotic lesions in apoE-/- mice
Robert J. Aiello et al.
ATHEROSCLEROSIS (2010)
Systemic MCP1/CCR2 blockade and leukocyte specific MCP1/CCR2 inhibition affect aortic aneurysm formation differently
Vivian de Waard et al.
ATHEROSCLEROSIS (2010)
A New Monocyte Chemotactic Protein-1/Chemokine CC Motif Ligand-2 Competitor Limiting Neointima Formation and Myocardial Ischemia/Reperfusion Injury in Mice
Elisa A. Liehn et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Enhancing search efficiency by means of a search filter for finding all studies on animal experimentation in PubMed
Carlijn R. Hooijmans et al.
LABORATORY ANIMALS (2010)
Therapeutic targeting of chemokine interactions in atherosclerosis
Rory R. Koenen et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Monocyte Chemoattractant Protein-1 (MCP-1): An Overview
Satish L. Deshmane et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2009)
HIV entry inhibitor TAK-779 attenuates atherogenesis in low-density lipoprotein receptor-deficient mice
EJA van Wanrooij et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2005)
Gene profiling in atherosclerosis reveals a key role for small inducible cytokines - Validation using a novel monocyte chemoattractant protein monoclonal antibody
E Lutgens et al.
CIRCULATION (2005)
Propagermanium: a nonspecific immune modulator for chronic hepatitis B
C Hirayama et al.
JOURNAL OF GASTROENTEROLOGY (2003)
Anti-monocyte chemoattractant protein-1 gene therapy limits progression and destabilization of established atherosclerosis in apolipoprotein E-knockout mice
S Inoue et al.
CIRCULATION (2002)
Propagermanium reduces atherosclerosis in apolipoprotein E knockout mice via inhibition of macrophage infiltration
T Yamashita et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2002)
分享论文
